Laurent Levy

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

Part of PDC Line Pharma SASU, PDC Line Pharma is a Belgian company that focuses on medical needs, particularly on skin cancer, which is the most lethal form of cancer worldwide. The company is based in Liege, Belgium, and has two drug candidates in its pipeline, one for melanoma and another for lung cancer. The company aims to address this issue by developing drug candidates that can bring positive results to patients. PDC Line Pharma was founded in 2016 by Laurent Levy and Joel Plumas, and its CEO is Eric Halioua.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.

PDC Line Pharma SASU develops an active immuno-therapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC line) loaded with cancer antigens. It offers PDC line which displays antigen presenting cell abilities allowing the priming of antitumor na?ve CD8+ cells in vitro and in vivo (humanized mouse model). The company was founded by Laurent Levy and Joel Plumas in April 2014 and is headquartered in Grenoble, France.